Skip to Content

How many biosimilars have been approved in the United States?

What are the biosimilars for Avastin, Enbrel, Epogen, Herceptin, Humira, Neulasta, Neupogen, Remicade, and Rituxan? ·

Medically reviewed by J. Stewart, BPharm. Last updated on Apr 25, 2019.

Official Answer


The number of biosimilars currently approved by the FDA is nineteen.

The most recent approval was Eticovo (etanercept-ykro) on April 25, 2019.

What is a biosimilar?
According the to FDA, a biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.

Avastin (bevacizumab) Biosimilars

  • Mvasi (bevacizumab-awwb)

Enbrel (etanercept) Biosimilars

Epogen / Procrit (epoetin alfa) Biosimilars

Herceptin (trastuzumab) Biosimilars

Humira (adalimumab) Biosimilars

Neulasta (pegfilgrastim) Biosimilars

Neupogen (filgrastim) Biosimilars

Remicade (infliximab) Biosimilars

Rituxan (rituximab) Biosimilars

More information: What Are Biosimilars? Top Facts You May Not Know

Other Medical Questions